Tianjin GreenPine Pharma

Executive Summary

Tianjin GreenPine Pharma is a privately-held Chinese pharmaceutical company founded in 2001, specializing in oncology and cardiovascular therapeutics. Operating through a hybrid model of in-house R&D and strategic international partnerships, the company focuses on licensing and commercializing imported drugs and medical devices for the Chinese market. By leveraging its expertise in regulatory navigation and quality control under Chinese frameworks, GreenPine has established a pipeline of selected global pharmaceutical products tailored to local needs. Despite being at the commercial stage with a lean employee base of 200–500, the company continues to expand its portfolio through selective licensing and internal development, positioning itself to address high-demand therapeutic areas in China's growing healthcare market. Its private status limits public disclosure of financials, but its targeted approach in oncology and cardiovascular segments suggests a focused growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026New Licensing Agreement for Oncology Drug70% success
• Q4 2026Regulatory Approval for Imported Cardiovascular Device65% success
• Q1 2027Launch of In-house Developed Oncology Candidate50% success